Interxion Schedules First Quarter 2019 Earnings Announcement

 

MEDIA ALERT: Marketing Evolution CEO to Speak at SAP’s European Executive Digital Exchange

 

QIAGEN N.V. to Report First Quarter 2019 Results

 

Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens

 

Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019

 

QIAGEN Launches First FDA-Approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

 

QIAGEN Highlights Profile of New QIAstat-Dx Meningitis / Encephalitis pAnel Focused on Most Prevalent Central Nervous System Pathogens

 

QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce availability of NeuMoDx 96 version

 

QIAGEN’s QuantiFERON®-TB Passes Milestone of 60 Million Tests in Global Fight against Tuberculosis, Current Annual Run Rate Exceeds 12 Million Tests

 

Topcon Introduces New Heads-Up Display for Hands-Free Construction Layout